Anupam Dalal
Direttore/Membro del Consiglio presso AADI BIOSCIENCE, INC.
Patrimonio netto: 3 M $ in data 31/05/2024
Profilo
Anupam Dalal is the founder of Kvp Capital Gp LLC.
He currently holds the position of Director at Aerpio Therapeutics, Inc., Director at Aadi Subsidiary, Inc., Independent Director at Aadi Bioscience, Inc., and Chief Investment Officer & Managing Member at Acuta Capital Partners LLC.
Previously, he served as Director at Neurotech Pharmaceuticals, Inc., Independent Director at Akebia Therapeutics, Inc., Managing Director at Kearny Venture Partners, Director at NewBridge Pharmaceuticals FZ LLC, Director at Taiwan Liposome Co., Ltd., Independent Director at Aerpio Pharmaceuticals, Inc., Principal at Pervasis Therapeutics, Inc., Principal at Resolvyx Pharmaceuticals, Inc., Principal at Flagship Pioneering, and Principal at Gilead Connecticut, Inc. Dr. Dalal completed his undergraduate degree at the University of California, Berkeley, his doctorate at the University of California, San Francisco, and his MBA at Harvard Business School.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
AADI BIOSCIENCES, INC.
7.54% | 12/06/2024 | 1 850 532 ( 7.54% ) | 3 M $ | 31/05/2024 |
Posizioni attive di Anupam Dalal
| Società | Posizione | Inizio |
|---|---|---|
| AADI BIOSCIENCE, INC. | Direttore/Membro del Consiglio | 26/08/2021 |
Acuta Capital Partners LLC
 Acuta Capital Partners LLC Financial ConglomeratesFinance Acuta Capital Partners LLC (ACP) is a registered investment adviser and hedge fund manager headquartered in Belmont, California. Formerly known as Longwood Capital Partners LLC, the firm was founded in 2011 and is a subsidiary of The Lin-Lay 2007 Trust. ACP provides investment management services, directly or through their affiliates, to several privately-offered, as well as to a separately managed account for a high-net worth individual. | Direttore degli Investimenti | 01/08/2016 |
Aerpio Therapeutics, Inc.
 Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Direttore/Membro del Consiglio | - |
Aadi Subsidiary, Inc.
 Aadi Subsidiary, Inc. BiotechnologyHealth Technology Aadi Subsidiary, Inc. engages in biopharmaceutical company. Its therapeutic programs include pulmonary arterial hypertension, pediatric solid tumors, solid tumors with mTOR activation and mitochondrial disease. The company was founded by Neil Desai and is headquartered in Pacific Palisades, CA. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Anupam Dalal
| Società | Posizione | Fine |
|---|---|---|
| AKEBIA THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 16/09/2016 |
Kearny Venture Partners
 Kearny Venture Partners Investment ManagersFinance Kearny Venture Partners (Kearny Venture Partners) is a venture capital firm. The firm is headquartered in San Francisco, California. | Investitore di Private Equity | 01/01/2016 |
Flagship Pioneering
 Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Investitore di Private Equity | 30/03/2006 |
Resolvyx Pharmaceuticals, Inc.
 Resolvyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Resolvyx Pharmaceuticals, Inc. discovers and develops therapeutics for inflammatory diseases. Its products include RX-10001, RX-10045 and RX-20001. The firm's focus is to develop a new class of medicines called Resolvins for the treatment of a range of ophthalmic diseases. The company was founded by Daniel Goodman, Charles N. Serhan, Per Gjorstrup and Thomas E. Van Dyke in June 20, 2001 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Pervasis Therapeutics, Inc.
 Pervasis Therapeutics, Inc. Medical SpecialtiesHealth Technology Pervasis Therapeutics, Inc. is a clinical stage company developing a broad portfolio of biologically active therapeutics. The company was founded by Robert S. Langer Jr. and Helen Marie Nugent in 2004 and is headquartered in Waltham, MA. | Corporate Officer/Principal | - |
Formazione di Anupam Dalal
| University of California, Berkeley | Undergraduate Degree |
| The University of California, San Francisco | Doctorate Degree |
| Harvard Business School | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| AKEBIA THERAPEUTICS, INC. | Health Technology |
| AADI BIOSCIENCE, INC. | Health Technology |
| Aziende private | 13 |
|---|---|
Pervasis Therapeutics, Inc.
Pervasis Therapeutics, Inc. Medical SpecialtiesHealth Technology Pervasis Therapeutics, Inc. is a clinical stage company developing a broad portfolio of biologically active therapeutics. The company was founded by Robert S. Langer Jr. and Helen Marie Nugent in 2004 and is headquartered in Waltham, MA. | Health Technology |
Resolvyx Pharmaceuticals, Inc.
Resolvyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Resolvyx Pharmaceuticals, Inc. discovers and develops therapeutics for inflammatory diseases. Its products include RX-10001, RX-10045 and RX-20001. The firm's focus is to develop a new class of medicines called Resolvins for the treatment of a range of ophthalmic diseases. The company was founded by Daniel Goodman, Charles N. Serhan, Per Gjorstrup and Thomas E. Van Dyke in June 20, 2001 and is headquartered in Cambridge, MA. | Health Technology |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Health Technology |
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Neurotech Pharmaceuticals, Inc. (United States)
 Neurotech Pharmaceuticals, Inc. (United States) Pharmaceuticals: MajorHealth Technology Neurotech Pharmaceuticals, Inc. designs and develops therapeutic systems for retinal diseases. The company was founded in 1995 and is headquartered in Cumberland, RI. | Health Technology |
Gilead Connecticut, Inc.
 Gilead Connecticut, Inc. Pharmaceuticals: MajorHealth Technology Gilead Connecticut, Inc. manufactures pharmaceuticals and biotechnology chemicals. The firm develops a pipeline of small molecule therapeutics for multiple oncology and immunology-based indications. It focuses on the development of novel kinase inhibitors for the treatment of cancer, autoimmune, and inflammatory diseases. The company was founded in 2000 and is headquartered in Foster City, CA. | Health Technology |
Kearny Venture Partners
Kearny Venture Partners Investment ManagersFinance Kearny Venture Partners (Kearny Venture Partners) is a venture capital firm. The firm is headquartered in San Francisco, California. | Finance |
NewBridge Pharmaceuticals FZ LLC
 NewBridge Pharmaceuticals FZ LLC Pharmaceuticals: MajorHealth Technology NewBridge Pharmaceuticals FZ LLC engages in the manufacture and distribution of pharmaceutical products, therapeutics and medical devices. The company was founded by G. Garrett Vygantas in 2007 and is headquartered in Dubai, United Arab Emirates. | Health Technology |
Taiwan Liposome Co., Ltd.
 Taiwan Liposome Co., Ltd. Pharmaceuticals: MajorHealth Technology Taiwan Liposome Co., Ltd. engages in the research and development of lipid-based formulation drugs. Its products are used for pain management, eye disease treatment, and cancer treatment. The company was founded by Kee Lung Hong on November 10, 1997 and is headquartered in Taipei, Taiwan. | Health Technology |
Acuta Capital Partners LLC
Acuta Capital Partners LLC Financial ConglomeratesFinance Acuta Capital Partners LLC (ACP) is a registered investment adviser and hedge fund manager headquartered in Belmont, California. Formerly known as Longwood Capital Partners LLC, the firm was founded in 2011 and is a subsidiary of The Lin-Lay 2007 Trust. ACP provides investment management services, directly or through their affiliates, to several privately-offered, as well as to a separately managed account for a high-net worth individual. | Finance |
Aerpio Pharmaceuticals, Inc.
 Aerpio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The firm's product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 16, 2007 and is headquartered in Cincinnati, OH. | Health Technology |
Aadi Subsidiary, Inc.
Aadi Subsidiary, Inc. BiotechnologyHealth Technology Aadi Subsidiary, Inc. engages in biopharmaceutical company. Its therapeutic programs include pulmonary arterial hypertension, pediatric solid tumors, solid tumors with mTOR activation and mitochondrial disease. The company was founded by Neil Desai and is headquartered in Pacific Palisades, CA. | Health Technology |
| Kvp Capital Gp LLC |
- Borsa valori
- Insiders
- Anupam Dalal
